OptimizeRx Corp (OPRX) stock
OPRXNasdaqServices-Business Services, NECFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 10/3030% below fair value
$6.94+0.30 (+4.52%)
Close on Nov 17, 2026Market cap $130.72MP/E 28.9Yield –
OptimizeRx r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $0. The highest annual figure on record is $1.60M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | – |
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $1.60M | – |
| FY2018 | Dec 31, 2018 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.27M | – |
| Q1 FY2026 | Mar 31, 2026 | $3.40M | – |
| Q2 FY2025 | Jun 30, 2025 | $3.09M | – |
| Q1 FY2025 | Mar 31, 2025 | $3.25M | – |
See a number that looks wrong?